169 related articles for article (PubMed ID: 8504423)
1. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.
Berkow RL; Schlabach L; Dodson R; Benjamin WH; Pettit GR; Rustagi P; Kraft AS
Cancer Res; 1993 Jun; 53(12):2810-5. PubMed ID: 8504423
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium.
Kraft AS; Adler V; Hall P; Pettit GR; Benjamin WH; Briles DE
Cancer Res; 1992 Apr; 52(8):2143-7. PubMed ID: 1559218
[TBL] [Abstract][Full Text] [Related]
3. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C.
Zhang X; Zhang R; Zhao H; Cai H; Gush KA; Kerr RG; Pettit GR; Kraft AS
Cancer Res; 1996 Feb; 56(4):802-8. PubMed ID: 8631017
[TBL] [Abstract][Full Text] [Related]
4. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
5. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity.
Hornung RL; Pearson JW; Beckwith M; Longo DL
Cancer Res; 1992 Jan; 52(1):101-7. PubMed ID: 1727368
[TBL] [Abstract][Full Text] [Related]
7. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis.
Grant S; Turner AJ; Freemerman AJ; Wang Z; Kramer L; Jarvis WD
Exp Cell Res; 1996 Oct; 228(1):65-75. PubMed ID: 8892972
[TBL] [Abstract][Full Text] [Related]
8. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells.
Scala S; Dickstein B; Regis J; Szallasi Z; Blumberg PM; Bates SE
Clin Cancer Res; 1995 Dec; 1(12):1581-7. PubMed ID: 9815959
[TBL] [Abstract][Full Text] [Related]
10. Biological activity of 26-succinylbryostatin 1.
Bignami GS; Wagner F; Grothaus PG; Rustagi P; Davis DE; Kraft AS
Biochim Biophys Acta; 1996 Jul; 1312(3):197-206. PubMed ID: 8703988
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of murine melanoma with bryostatin 1.
Schuchter LM; Esa AH; May S; Laulis MK; Pettit GR; Hess AD
Cancer Res; 1991 Jan; 51(2):682-7. PubMed ID: 1985785
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C.
Isakov N; Galron D; Mustelin T; Pettit GR; Altman A
J Immunol; 1993 Feb; 150(4):1195-204. PubMed ID: 8432975
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of novel protein kinase C delta in BL6 murine melanoma cells inhibits the proliferative capacity in vitro but enhances the metastatic potential in vivo.
La Porta CA; Di Dio A; Porro D; Comolli R
Melanoma Res; 2000 Apr; 10(2):93-102. PubMed ID: 10803709
[TBL] [Abstract][Full Text] [Related]
14. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration.
Bear HD; McFadden AW; Kostuchenko PJ; Lipshy KA; Hamad GG; Turner AJ; Roberts JD; Carr M; Carr S; Grant S
Anticancer Drugs; 1996 May; 7(3):299-306. PubMed ID: 8792004
[TBL] [Abstract][Full Text] [Related]
15. The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow.
Koutcher JA; Motwani M; Zakian KL; Li XK; Matei C; Dyke JP; Ballon D; Yoo HH; Schwartz GK
Clin Cancer Res; 2000 Apr; 6(4):1498-507. PubMed ID: 10778982
[TBL] [Abstract][Full Text] [Related]
16. Bryostatin-1 enhances the maturation and antigen-presenting ability of murine and human dendritic cells.
Do Y; Hegde VL; Nagarkatti PS; Nagarkatti M
Cancer Res; 2004 Sep; 64(18):6756-65. PubMed ID: 15374994
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
18. Posttranslational regulation of Lck and a p36-38 protein by activators of protein kinase C: differential effects of the tumor promoter, PMA, and the non-tumor-promoter, bryostatin.
Galron D; Ansotegui IJ; Isakov N
Cell Immunol; 1997 Jun; 178(2):141-51. PubMed ID: 9225005
[TBL] [Abstract][Full Text] [Related]
19. The differentiation inducing effect of bryostatin 5 on human myeloid blast cells is potentiated by vitamin D3.
van der Hem KG; Dräger AM; Huijgens PC; Tol C; Devillé W; Langenhuijsen MM
Leukemia; 1994 Feb; 8(2):266-73. PubMed ID: 7508534
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulating properties of a novel series of protein kinase C activators. The bryostatins.
Trenn G; Pettit GR; Takayama H; Hu-Li J; Sitkovsky MV
J Immunol; 1988 Jan; 140(2):433-9. PubMed ID: 3257237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
